While targeting the IDH metabolic pathway with IDH inhibitors, and also more recently the IDH antigen, has demonstrated encouraging preliminary results in IDH mutated gliomas (95), glioblastoma or IDH wild type gliomas lack a uniformly expressed tumor specific antigen and are highly heterogenous. This evidence concerns the gene IDH1 and glioma.